Who Is Eligible for CAR-T Cell Therapy? Prior Treatments, Cancer Type and Fitness Checks

The oncologist said the word twice before it registered. “Referral.” Not to another chemotherapy, not to hospice, but to a specialized center that would decide whether a third relapse of lymphoma made a person a candidate for something built from their own blood. Driving home, the questions arrived faster than the exits: Am I too old? Too sick? Did the earlier treatments help or hurt my chances? CAR T cell therapy eligibility turns out to be a real, structured assessment, and understanding it takes some of the fear out of the waiting.

This explainer walks through what the referral team is actually checking. Some of it is about the cancer itself, some about the treatments that came before, and a surprising amount is about the heart, lungs and kidneys of the person carrying the cancer around.

None of this replaces the conversation with your own team. It is meant to help you have a better one.

What does CAR T cell therapy eligibility actually depend on?

Strip away the jargon and CAR T cell therapy eligibility comes down to three questions, asked in roughly this order. Does the cancer carry a protein that an approved CAR-T product is built to recognize? Has the disease already come back or resisted the standard treatments that guidelines say should be tried first? And can this particular person, with this particular heart, kidneys and energy level, get through several weeks of intensive treatment and its known side effects?

Each question is answered by a different set of evidence. The first is settled largely by pathology: a biopsy report and laboratory tests that confirm the diagnosis and, where relevant, the target protein on the cancer cells. The second comes from the treatment history sitting in your records, including how the cancer responded and how long any remission lasted. The third is the part most people underestimate. It involves a physical exam, blood tests, heart imaging, sometimes lung function tests, and a frank assessment of how you manage day-to-day activities. The National Cancer Institute describes CAR-T as a treatment currently reserved for people whose blood cancers have not responded to, or have returned after, other treatments, precisely because it carries serious risks that only make sense when the alternatives are limited.

The decision is not made by one doctor in one appointment. A specialist CAR-T center reviews every referral, often through a formal multidisciplinary panel that includes hematologists, immunotherapy nurses, pharmacists and sometimes intensive-care specialists. In the NHS, for example, a national clinical panel reviews cases before treatment is approved. The purpose is the same everywhere: to match a demanding therapy to the people most likely to tolerate it and least likely to be well served by anything else.

How does CAR-T cell therapy work, in plain language?

T cells are white blood cells that patrol the body looking for infected or abnormal cells. Cancer often hides from them. CAR-T therapy, short for chimeric antigen receptor T-cell therapy, gives those patrol cells a new sensor so they can see the cancer again.

Here is what happens. A machine collects T cells from your bloodstream in a process called leukapheresis, which draws blood, filters out the white cells and returns the rest, much like a long dialysis session. The collected cells are sent to a laboratory, where a harmless, modified virus delivers a new gene into them. That gene instructs each T cell to build a receptor on its surface, the chimeric antigen receptor, engineered to lock onto a specific protein on the cancer cell, such as CD19 on many B-cell lymphomas and leukemias or BCMA on myeloma cells. The lab then grows the modified cells into the millions.

Before the cells come back, most people receive a short course of chemotherapy called lymphodepletion. Its job is not to treat the cancer directly but to clear space in the immune system so the engineered cells can expand once infused. The infusion itself is often surprisingly undramatic, delivered through a vein much like a blood transfusion. Afterward, the cells multiply inside the body and begin attacking cells that display the target protein.

Because the cells are living, they behave differently from a drug that is cleared in hours. They can persist for months, which is why some effects, including low antibody levels, can outlast the treatment itself. The Cleveland Clinic and the National Cancer Institute both describe manufacturing as taking several weeks, a delay that becomes an eligibility factor in its own right, as a later section explains.

Which cancer types currently qualify for CAR-T?

Approved CAR-T treatments are currently limited to certain blood cancers. The National Cancer Institute lists three broad groups: B-cell lymphomas, including large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma in specific circumstances; B-cell acute lymphoblastic leukemia, or B-ALL; and multiple myeloma, a cancer of plasma cells in the bone marrow.

The common thread is the target. Products for lymphoma and B-ALL recognize CD19, a protein found on most B cells, healthy and cancerous alike. Products for myeloma recognize BCMA, a protein on plasma cells. If your cancer does not display one of these targets, a currently approved CAR-T is not designed to find it, no matter how advanced the disease is. That is why the pathology report, and sometimes a repeat biopsy, sits at the front of the eligibility check.

Solid tumors, such as lung, breast or colon cancer, are not currently treatable with approved CAR-T products. Research is active, and clinical trials are recruiting, but the National Cancer Institute is clear that these remain investigational. A person with a solid tumor who asks about CAR-T should hear an honest answer: the science is promising, the approved options are not there yet, and any access would be through a trial with its own entry rules.

Within the approved cancers, subtype matters too. Different lymphoma subtypes have different approval conditions and different amounts of supporting evidence. A team may agree that CAR-T is appropriate for one subtype after two failed treatments but not yet supported for a closely related one. This is not arbitrary; it reflects which patient groups were studied in the trials that led to approval. Your team can tell you exactly which category your diagnosis falls into and what the evidence looks like for it.

Why prior treatments matter: the lines of therapy question

A “line” of therapy is one complete course of treatment given for a cancer, whether that is a chemotherapy combination, a targeted drug, a stem cell transplant or immunotherapy. When the cancer progresses and a different treatment starts, that counts as a new line. CAR-T eligibility criteria are written in these terms because the approval trials enrolled people at defined points in their treatment journey.

Historically, CAR-T was approved only after at least two earlier lines had failed. For some lymphoma settings, the National Cancer Institute notes that approvals now extend to people whose disease returned quickly after, or never responded to, first-line treatment. For B-ALL and myeloma, the required number of prior treatments varies by product and age group. The practical message is that the number of lines you have had is not just a count; it is evidence about how the cancer behaves and which trial population you most resemble.

Timing within that history counts as well. Disease that comes back within a year of first treatment tends to be handled differently from disease that stayed away for several years. Response to the most recent treatment, or the lack of one, also shapes the discussion, because it hints at how aggressive the cancer is now.

A frequent worry is that earlier treatments might have “used up” the T cells needed for manufacturing. Certain chemotherapy drugs and some targeted treatments can lower T-cell numbers or affect their fitness, and centers do consider recent therapy when planning collection timing. This rarely rules someone out on its own, but it is one reason referral teams prefer to see people earlier rather than later, before more treatments have been layered on. Bring a full list of everything you have received and the approximate dates; it genuinely changes the assessment.

Is there a CAR-T cell therapy age limit?

There is no fixed upper age limit for adults. What exists instead is a fitness assessment, and age is one input among many. A person in their late seventies who walks daily, has a strong heart and well-controlled blood pressure may be a better candidate than someone two decades younger with advanced heart failure and poor kidney function. Centers look at biological fitness, not the number on a birth certificate.

Age does appear in eligibility criteria in a different way: at the younger end. The National Cancer Institute notes that the CAR-T product approved for B-cell acute lymphoblastic leukemia in children and young adults covers patients up to age 25 whose disease has not responded or has relapsed. Other products for lymphoma and myeloma are approved for adults. So a teenager with relapsed B-ALL and a 30-year-old with the same disease may be steered toward different options, not because one is sicker but because the approvals were built on different trial populations.

Older adults face a genuinely higher risk of some side effects, particularly neurological toxicity, and recovery of blood counts can be slower. Teams weigh this honestly. It does not translate into automatic exclusion; it translates into a more careful look at heart function, mental sharpness, frailty and the support available at home.

Frailty assessment deserves a specific mention. Some centers use formal geriatric assessment tools that look at walking speed, grip strength, nutrition and independence with daily tasks. These often predict how someone will cope with intensive treatment more accurately than age alone. If you are older and wondering whether to even ask about CAR-T, ask. The answer is a conversation, not a cutoff.

Who is a good candidate for CAR-T, and who is usually asked to wait?

Picture the person referral teams tend to describe as a straightforward candidate. The diagnosis is one of the approved cancers with a confirmed target protein. The disease has returned or resisted the guideline-recommended earlier treatments. The person can walk into clinic, manage personal care and spend at least part of the day up and about. Blood tests show kidneys and liver working reasonably, the heart pumps adequately on imaging, and there is no active infection. A caregiver is available for the weeks after infusion. None of these has to be perfect, but each has to be good enough.

Who is usually asked to wait, rather than refused outright? Someone with an active, uncontrolled infection, because lymphodepleting chemotherapy and the inflammatory storm that can follow infusion would make it far more dangerous. Someone whose cancer is growing so fast that it would overtake the weeks needed to manufacture cells; the team may treat first and reassess. Someone recovering from a recent stem cell transplant with ongoing graft-versus-host disease, in which donor immune cells attack the recipient’s tissues, since adding engineered T cells could worsen it. Someone whose heart or kidney function has dipped temporarily because of recent treatment may be re-evaluated after recovery.

A smaller group is usually advised against CAR-T altogether: people with severe, irreversible organ failure, uncontrolled cancer in the brain or spinal cord that would compound neurological risk, or a level of frailty where the treatment is more likely to harm than help. Even here, teams frame the conclusion as a clinical judgment about safety, not a verdict on worth.

Between the clear yes and the clear no sits a wide middle, and that is where most real decisions live. The Cleveland Clinic describes CAR-T as intensive treatment requiring close monitoring; the eligibility process is essentially an honest prediction of whether that intensity is survivable and worthwhile for you.

Fitness checks: heart, lungs, kidneys, liver and performance status

The fitness work-up exists because CAR-T can trigger cytokine release syndrome, a body-wide inflammatory reaction in which activated immune cells flood the bloodstream with signaling chemicals, producing fever, low blood pressure and, in severe cases, organ strain. A body with reserve absorbs that hit. A body without reserve may not. So the tests are less about the cancer than about your margin of safety.

Performance status comes first. Doctors commonly use a simple scale (ECOG) that runs from fully active with no restrictions to bedbound. Most CAR-T eligibility criteria expect someone to be at least capable of self-care and up and about for more than half the day. It sounds crude, but it predicts tolerance of intensive treatment remarkably well.

Heart function is assessed with an echocardiogram, an ultrasound that measures how effectively the heart pumps, and an ECG to check rhythm. Low blood pressure during cytokine release syndrome puts direct demand on the heart, so a weakened pump is a serious concern. Lung function may be checked with breathing tests or oxygen saturation, since fluid shifts and inflammation can affect breathing.

Kidney and liver function are read from blood tests. Both organs clear drugs used during lymphodepletion and process the byproducts of a large immune response. Impaired function does not automatically exclude someone, but it changes how the team plans supportive care and how much risk they judge acceptable.

Neurological baseline matters because CAR-T can cause a temporary neurotoxicity, sometimes called ICANS, with confusion, word-finding difficulty or, rarely, seizures. Teams document handwriting, orientation and attention before treatment so changes afterward can be spotted quickly. Pre-existing conditions such as dementia or a recent stroke raise the stakes and are weighed carefully.

Infections, immune conditions and other health checks before referral

Infection screening is standard and thorough. Blood tests look for HIV, hepatitis B and hepatitis C, not because a positive result is automatically disqualifying but because these viruses can reactivate or worsen when the immune system is suppressed, and the team needs a plan. Active bacterial or fungal infections generally need to be controlled before lymphodepleting chemotherapy begins.

Autoimmune conditions get a careful look. Diseases such as lupus, rheumatoid arthritis or inflammatory bowel disease involve an immune system already inclined to attack the body, and engineered T cells plus the inflammatory environment of cytokine release syndrome could, in theory, intensify that. Mild, well-controlled disease is often manageable. Severe or unstable disease, especially if it requires strong immune-suppressing medicines, complicates the picture, and any such medicine would need to be reviewed by the prescribing team because it may interfere with the engineered cells.

A previous allogeneic stem cell transplant, in which blood-forming cells came from a donor, raises specific questions. If donor cells have caused graft-versus-host disease, adding another immune-active treatment is risky. Centers typically want that condition quiet and off heavy immunosuppression before proceeding.

Central nervous system involvement is assessed by imaging or spinal fluid testing where indicated. Cancer in the brain or spinal cord does not always exclude CAR-T, but the neurotoxicity risk is higher and the team’s threshold changes.

Practical circumstances count too. The Cleveland Clinic advises that people stay close to their treatment center for several weeks after infusion and avoid driving for a period afterward, and a caregiver is generally required during that time. A referral team will ask about home support early, not as a judgment but because a patient who cannot be safely monitored is a patient at risk.

Can your cancer wait for the cells to be made?

This is the eligibility factor that catches people off guard. CAR-T is not sitting on a shelf. Once T cells are collected, they travel to a manufacturing facility, are modified and expanded, tested for quality and shipped back. The National Cancer Institute describes this as taking several weeks. During that window the cancer does not pause.

A referral team therefore asks a blunt question: is this disease likely to stay controllable while we wait? Slowly progressing lymphoma often is. Rapidly growing disease with rising markers, new symptoms or organ compression may not be. In that case the team faces a choice. They may proceed with collection and use bridging therapy, a holding treatment given between collection and infusion to keep the cancer in check without damaging the manufacturing process. Or they may decide the disease needs immediate conventional treatment first, with CAR-T revisited later.

Bridging therapy is chosen carefully. It has to be effective enough to buy time but gentle enough on the immune system that the eventual engineered cells can still take hold. Radiation to a single bulky area, a short course of chemotherapy or a targeted drug are common approaches. The specifics are entirely the treating team’s call and depend on the cancer subtype.

Manufacturing itself can occasionally fail, or produce too few cells, particularly when collected T cells were weakened by earlier treatments. Centers plan for this possibility and will discuss it upfront. It is uncommon, but it is one more reason the disease tempo question matters: a cancer that could tolerate one manufacturing cycle might not tolerate two.

If your team says your cancer is moving too fast right now, that is not a closed door. It is a sequencing decision, and sequencing can change once the disease is steadier.

CAR-T cell therapy criteria at a glance

The table below gathers the main CAR-T cell therapy criteria into one view. It is a summary of what specialist teams commonly assess, not a checklist you can score yourself; each line is interpreted alongside the others.

Area assessed	What generally supports eligibility	What usually prompts a wait or a no
Cancer type and target	Approved B-cell lymphoma subtype, B-ALL or multiple myeloma with the relevant target protein confirmed	Solid tumor; target protein absent; subtype without approval
Prior treatments	Disease returned or resistant after guideline-recommended earlier lines	Standard first-line treatment not yet tried when it is still appropriate
Age	No fixed upper limit for adults; pediatric B-ALL products cover children and young adults up to age 25	Age alone rarely decides; frailty does
Performance status	Capable of self-care and active for much of the day	Bedbound or largely dependent
Heart, lungs, kidneys, liver	Adequate function on imaging and blood tests	Severe or irreversible organ failure
Infection	No active uncontrolled infection; viral screens addressed	Active bacterial, fungal or uncontrolled viral infection
Neurological status	Stable baseline; no active brain or spinal cord disease, or disease judged manageable	Uncontrolled CNS involvement; recent stroke; significant dementia
Disease tempo	Controllable during several weeks of manufacturing, with or without bridging	Progressing too quickly to wait
Support at home	Caregiver available; able to stay near the center for the monitoring period	No safe monitoring arrangement

Two things stand out when the criteria sit side by side. First, only one row is truly fixed: the cancer must be one the approved products are built for. Second, almost every other row is a judgment of degree, which is why the same person can be told “not yet” at one visit and “let’s proceed” a few months later.

The CAR-T cell therapy process: what happens once you're approved

Approval sets off a sequence that runs over roughly two months, though the exact timeline is set by your center. The Johns Hopkins Medicine overview describes the main stages: collection, manufacturing, preparatory chemotherapy, infusion and monitoring.

Collection comes first. Leukapheresis is usually done as an outpatient over several hours, through a large vein in the arm or a temporary central line. Most people find it tedious rather than painful; the main sensations are cold, tingling from a calcium shift that nurses correct as they go, and the boredom of lying still. The collected cells leave for manufacturing the same day.

The waiting weeks follow. Some people receive bridging therapy, others simply have regular checks. This is the time to arrange the caregiver, the accommodation near the center if needed, and time off work. Many centers also complete final fitness rechecks now, since organ function can shift between referral and infusion.

Lymphodepletion is typically a few consecutive days of chemotherapy in the week before infusion. Its purpose, as earlier described, is to make room for the engineered cells. Side effects are usually milder than treatment chemotherapy but include fatigue, nausea and a further dip in blood counts. Infusion follows a day or two later and is often short, sometimes under half an hour, delivered through a vein.

Monitoring is the long tail. Some centers admit people to hospital for the first week or more; others use intensive outpatient monitoring with daily visits. The Cleveland Clinic notes that patients are asked to remain close to the center for at least four weeks after infusion and to avoid driving or hazardous activities for around eight weeks because of the possibility of delayed neurological effects. The eligibility team will have asked about all this before approving you, which is why the practical questions arrive so early.

What the following days and weeks usually look like

The first two weeks after infusion are when the two signature side effects most often appear, and the whole monitoring plan is built around them.

Cytokine release syndrome commonly begins within days. The earliest sign is usually fever, sometimes high, followed in some people by low blood pressure, fast heart rate, low oxygen levels and fatigue that feels like a severe flu. The National Cancer Institute describes it as ranging from mild to life-threatening. Teams grade it hourly and have medicines that dampen the inflammatory signal; when to use them is entirely the treating team’s decision. Most cases settle within days to a week or two.

Neurotoxicity, or ICANS, tends to arrive a little later, often in the second week, and can overlap with or follow cytokine release syndrome. Early signs are subtle: trouble finding words, sloppy handwriting, confusion about the date, unusual drowsiness. This is why nurses ask you to write the same sentence every day. The caregiver requirement exists largely for this; the person experiencing these changes is often the last to notice them.

Blood counts are typically low for weeks. Lymphodepletion knocks them down, and recovery can be slow and occasionally prolonged for months. Infection precautions, transfusions and growth-factor support may be used according to the team’s judgment.

By the end of the first month, most people are past the acute phase and attending less frequent visits. Fatigue often lingers longer than anything else. A first response assessment, usually with imaging or bone marrow testing, is commonly scheduled around one to three months after infusion, though timing varies by cancer type and center.

Longer term, because CD19-directed cells also remove healthy B cells, antibody levels can stay low for months or longer. Teams monitor this and may recommend supportive measures. Vaccination plans are also revisited, following guidance for people with weakened immune systems.

Alternatives if CAR-T isn't an option right now

Being told CAR-T is not suitable, or not suitable yet, does not mean the treatment conversation is over. The alternatives depend heavily on cancer type and earlier treatment, and they are the treating team’s to lay out. A few categories come up repeatedly.

Bispecific antibodies are a newer class of immunotherapy that work on a related principle. Instead of engineering your T cells outside the body, these off-the-shelf medicines physically link a T cell to a cancer cell so the T cell attacks it. They carry some of the same inflammatory risks as CAR-T but require no manufacturing wait, which makes them relevant for fast-moving disease. Availability and approval vary by cancer type.

Stem cell transplant remains a standard option for some people with relapsed lymphoma or leukemia. An autologous transplant uses the person’s own stored stem cells after high-dose chemotherapy; an allogeneic transplant uses a donor’s. Fitness requirements are demanding, sometimes more so than CAR-T, so a person deemed too frail for one may be too frail for the other.

Targeted drugs, antibody-drug conjugates and newer chemotherapy combinations continue to expand for both lymphoma and myeloma. Some are given as tablets or outpatient infusions and suit people who need less intensive treatment.

Clinical trials deserve an honest mention. Trials of CAR-T for solid tumors, of newer targets and of CAR-T in earlier lines are recruiting. Each trial has its own eligibility rules, sometimes stricter than approved treatments, sometimes more flexible. Asking your team whether a trial fits is a reasonable step and does not commit you to anything.

Palliative and supportive care runs alongside all of these, not instead of them. For some people, focusing on quality of life is the right choice, and a good team will say so plainly and without pressure.

What people often get wrong about CAR-T eligibility

The first misconception is that CAR-T is a last resort you must fail everything to reach. That was closer to true when approvals were limited to the third line. For some lymphoma subtypes, the National Cancer Institute notes approvals now reach people whose disease returned quickly after first treatment. Waiting too long can actually reduce eligibility, because each additional treatment can weaken T cells and lower fitness. Earlier referral for an opinion is reasonable, even when the answer is “not yet.”

The second is that age decides. It does not, at least not on its own. Adults in their seventies and beyond are treated when fitness allows. The one place age is written into criteria is the pediatric B-ALL approval, which extends to young adults up to 25.

The third is that CAR-T works for any cancer. It is currently approved only for certain B-cell lymphomas, B-ALL and multiple myeloma. People with solid tumors are sometimes told otherwise by online forums; the evidence there is limited to trials.

The fourth is that a single test settles eligibility. There is no CAR-T blood test. The decision is a composite of pathology, treatment history, organ function, infection status, disease tempo and home support, reviewed by a panel.

The fifth is that a “no” is permanent. Many refusals are really deferrals: an infection needs treating, the disease needs steadying, kidney function needs to recover, a caregiver needs to be found. Ask specifically whether the barrier is fixed or changeable.

The sixth is that fitter people sail through without side effects. Fitness reduces risk; it does not remove it. Cytokine release syndrome and neurotoxicity can affect anyone who receives engineered cells, which is exactly why the monitoring requirements apply to everyone, however well they feel walking in.

Questions to ask your care team

Bring these to the referral appointment or the eligibility discussion. Write the answers down, or ask a companion to; a lot arrives at once.

• Does my exact cancer subtype have an approved CAR-T product, and does my biopsy confirm the target protein?
• Where does my treatment history place me in relation to the current eligibility criteria, and does the number of prior lines help or hinder?
• Which fitness tests will you run, and are any of my results borderline? If so, is there anything that could improve them before a decision?
• Is my disease moving slowly enough to wait for manufacturing, or would I need bridging therapy? What would that involve?
• Are any of my current medicines a concern for T-cell collection or for the engineered cells afterward? (Do not change anything yourself; ask the prescriber.)
• If I am not eligible now, is the barrier fixed or temporary, and what would need to change?
• What are the alternatives you would consider for me, and how do their risks compare?
• How long would I need to stay near the center, and what caregiver arrangement do you require?
• What side effects are you most concerned about for someone with my health profile, and how would you monitor for them?
• Is there a clinical trial, here or elsewhere, that might fit my situation?
• Who do I call, at any hour, if I develop a fever or feel confused after infusion?

One more question is worth asking of yourself: what matters most to you in the months ahead? Some people prioritize the possibility of a long treatment-free period even at the cost of an intense few weeks. Others prioritize staying home and avoiding hospital. Neither is wrong, and a good team will want to know which describes you before recommending anything.

When to call your doctor

If you are being assessed for CAR-T, or have received it, certain symptoms need same-day medical contact rather than a wait for the next appointment. Your center will give you a direct number; use it without hesitation.

Seek urgent care immediately, or call emergency services, for any of the following after infusion: a fever, which the Cleveland Clinic and National Cancer Institute both flag as the earliest common sign of cytokine release syndrome; chills or shaking; dizziness, fainting or a racing heart, which can signal falling blood pressure; shortness of breath or new difficulty breathing; confusion, trouble speaking or finding words, unusual sleepiness, difficulty writing, or any seizure, all of which may indicate neurotoxicity and require rapid assessment. Caregivers should treat any change in alertness or personality as an emergency, since the person affected may not recognize it.

Contact your team the same day for signs of infection such as a cough with phlegm, burning on urination, redness around a line site or persistent diarrhea, since blood counts and antibody levels may be low for weeks to months. Unusual bleeding or bruising, severe headache, or a rash that spreads quickly also warrant a call.

Before treatment, during the assessment period, tell your team promptly about any new fever, new pain, swelling, breathlessness or a sudden drop in your usual energy. These can indicate that the cancer is changing pace or that an infection is developing, and both affect eligibility timing.

Every decision about testing, treatment, deferral and supportive medicines rests with your treating team. This article is a guide to the conversation, not a substitute for it.

Frequently asked questions

Who is a good candidate for CAR T-cell therapy?

A good candidate typically has one of the approved blood cancers (certain B-cell lymphomas, B-ALL or multiple myeloma) that has returned or resisted earlier treatment, adequate heart, kidney, liver and lung function, no active uncontrolled infection, a stable neurological baseline, and disease that can be held steady during the weeks of cell manufacturing. Home support and the ability to stay near the center also matter. A specialist team makes the final call after testing.

Is there an age limit for CAR T-cell therapy?

There is no fixed upper age limit for adults. Fitness, organ function and frailty are assessed instead, and people in their seventies and beyond are treated when those allow. Age appears in criteria mainly at the younger end: the National Cancer Institute notes the pediatric B-cell acute lymphoblastic leukemia product covers children and young adults up to age 25, while lymphoma and myeloma products are approved for adults.

How much does CAR T-cell therapy cost?

This article does not discuss prices, and cost should not be confused with eligibility, which is a medical assessment. Coverage arrangements differ widely between health systems and insurance plans, and the treatment center’s financial counselors or your national health service are the right people to explain what applies to you. Ask the referral team early, since practical arrangements such as accommodation and time off work also need planning.

Which country is best for CAR T-cell therapy?

Eligibility does not depend on geography, and no country or center is medically superior for everyone. The same core criteria, cancer type, prior treatment, organ fitness and disease tempo, apply wherever the assessment takes place. Traveling for treatment adds practical burdens, including the requirement to stay near the center for several weeks and to have a caregiver present. Discuss options with your own treating team before considering any travel.

What are the main CAR T-cell therapy criteria a center checks?

Centers check the cancer subtype and confirm the target protein, review how many treatments you have had and how the disease responded, assess performance status, heart function by echocardiogram, kidney and liver blood tests, infection screens including hepatitis and HIV, neurological baseline, any brain or spinal cord involvement, autoimmune or transplant history, and whether the disease can wait for manufacturing. Home support is also confirmed.

Can you have CAR-T if the cancer has spread to the brain?

Sometimes, but it raises the stakes. Cancer in the brain or spinal cord increases the risk of neurotoxicity, one of the two signature side effects, so teams assess it carefully with imaging or spinal fluid testing. Some people with controlled central nervous system disease are treated; uncontrolled involvement is often a reason to defer or to choose another approach. The decision rests with the specialist team.

How long does the CAR T-cell therapy process take from referral to infusion?

It varies, but the National Cancer Institute describes manufacturing alone as taking several weeks after cells are collected. Add time for eligibility testing before collection and a few days of preparatory chemotherapy before infusion, and the full pathway commonly spans around two months, followed by at least four weeks of close monitoring near the center according to Cleveland Clinic guidance. Your center will give you its own timeline.

Does a previous stem cell transplant stop you from having CAR-T?

Not automatically. Many people who received CAR-T had an earlier autologous transplant using their own cells. A previous donor (allogeneic) transplant needs closer review: if donor cells have caused graft-versus-host disease, adding engineered T cells could worsen it, so teams generally want that condition quiet and off heavy immunosuppression first. Your transplant history is one of the first things the referral team will ask about.

Can CAR-T be used for solid tumors like breast or lung cancer?

Not with currently approved products. The National Cancer Institute lists approvals only for certain B-cell lymphomas, B-cell acute lymphoblastic leukemia and multiple myeloma. Research into CAR-T for solid tumors is active and clinical trials are recruiting, but these remain investigational. Anyone with a solid tumor interested in CAR-T should ask their oncologist about trials rather than expecting an approved treatment.

If I'm told I'm not eligible for CAR-T, is that final?

Often it is not. Many refusals are deferrals tied to changeable factors: an infection that needs treatment, disease progressing too fast to wait for manufacturing, kidney or heart function that dipped after recent chemotherapy, or a missing caregiver arrangement. Ask your team directly whether the barrier is fixed or temporary and what would need to change. Alternatives such as bispecific antibodies, transplant or clinical trials may also be discussed.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.